Biophytis - LIVE HEALTHIER LONGER

Trusted

http://www.biophytis.com/

Last activity: 13.03.2026

Active

Categories: AgingBioTechClinicalLongevityPharma

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs.

Specifically, the company is advancing two proprietary drug candidates into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD).

The business model of BIOPHYTIS is to ensure the conduct of the project until clinical activity in the patient is proven, then to license the technologies in order to continue the development in partnership with a pharmaceutical laboratory.

The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and collaborates with scientists at the Institute of Myology, and the Vision Institute

Twitter LinkedIn

Followers

1.96K

Followers

3.18K

Mentions

Overview

Location

France

Employees

11-50

Total raised

$48.25M

Founded date

2006

Investors 1

Date	Name	Website
Sign up to see	Sign up to see	Sign up to see

Funding Rounds 6

Date	Series	Amount	Investors
Sign up to see	Sign up to see	Sign up to see	Sign up to see
Sep 13, 2018	Funding round	$11.63M
Nov 1, 2017	Funding round	$8.74M
Oct 11, 2017	Funding round	$12.34M
Jul 29, 2016	Funding round	$1.23M
Oct 1, 2012	Series B round	$2.6M

Mentions in press and media 30

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Mar 14, 2025	Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing	Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the p...
May 10, 2023	Biophytis Launches a Round of Fundraising for Approximately 2 Million Euros
Feb 2, 2023	Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19	COVA study met primary end point with 44% significant reduction in the risk of respiratory failure or early death Filing for Early Access Programs to Sarconeos (BIO101) is being initated while preparing for Marketing Authorisation in Europe...
Feb 2, 2023	Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19	COVA study met primary end point with 44% significant reduction in the risk of respiratory failure or early death Filing for Early Access Programs to Sarconeos (BIO101) is being initated while preparing for Marketing Authorisation in Europe...
Jan 12, 2023	Biophytis To Take Appropriate Measures After Receiving Nasdaq Deficiency Notice	PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / January 12, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the developmen...
Jan 5, 2023	Biophytis Announces Its Participation in Two Major Investor Conferences in January, In the United States and In France: The JP Morgan Healthcare Conference and The Invest Securities Biomed	PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / January 5, 2023 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "company") a clinical-stage biotechnology company focused on the development...
Dec 1, 2022	Biophytis Organises a Webcast with Key Opinion Leaders (KOL) On the Phase 2-3 Cova Study Results of Sarconeos (Bio101) In the Treatment of Pneumonia in Covid-19 Patients at Risk of Respiratory Failure	Following the positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in the treatment of pneumonia in COVID-19 patients at risk of repiratory failure, Biophytis manage...
Nov 3, 2022	Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19	A reduction in the risk of early death or respiratory failure at day 28 of 45% in the Intent-To-Treat (ITT) population and 53% in the Per Protocol (PP) population A reduction in the risk of death at day 90 of 43% in the ITT population and 7...
Oct 31, 2022	Biophytis Publishes Its Key Financial Figures As at 30 June 2022, Announces a Restatement of the Financial Statements Published As of December 31st, 2021 and Provides an Update on the Operational Milestones	PARIS, FRANCE and CAMBRIDGE, MASSACHUSETTS / ACCESSWIRE / October 31, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the d...
Jun 30, 2022	Biophytis Announces the Drawing of the Second Tranche of Ornane Under the 2021 Atlas Contract for €4 Million	PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 30, 2022 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processe...
Jun 3, 2022	Biophytis: Convening of Another Combined General Meeting at a Later Date	PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 3, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on the development of ...
Apr 7, 2022	Biophytis Provides Updates on Sarconeos (BIO101) Clinical Development	Sarcopenia (SARA) : discussions engaged with FDA for the preparation of a Phase 2-3 program in sarcopenia, with the objective of having a First Patient In by end of H2 2022 COVID-19 (COVA): 237 patients enrolled - early termination of recru...
Apr 7, 2022	Biophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives	Success of Nasdaq IPO in February 2021 €23.9M of available cash on December 31 2021 and new financing instruments for a total of €42M allowing financial visibility beyond mid 2023 Strong growth of operational expenses to €26.8M, mainly refl...
Apr 5, 2022	Biophytis Appoints Philippe Rousseau as Chief Financial Officer	PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 5, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company specialized in the development...
Feb 3, 2022	Biophytis received approval from ANVISA (Brazil) to give access to Sarconeos (BIO101) to hospitalized COVID-19 patients through an Expanded Access Program	Biophytis / Key word(s): Miscellaneous Biophytis received approval from ANVISA (Brazil) to give access to Sarconeos (BIO101) to hospitalized COVID-19 patients through an Expanded Access Program 03-Feb-2022 / 08:38 CET/CEST Biophytis receive...
Dec 23, 2021	Biophytis announces the drawing of the last tranche of ORNANE under the 2020 Atlas Contract for ?3 million	Biophytis / Key word(s): Miscellaneous Biophytis announces the drawing of the last tranche of ORNANE under the 2020 Atlas Contract for ?3 million 22-Dec-2021 / 23:00 CET/CEST Biophytis announces the drawing of the last tranche of ORNANE und...
Dec 16, 2021	Biophytis to meet with FDA to advance Sarconeos (BIO101) development in Sarcopenia from Phase 2 to Phase 3	Biophytis / Key word(s): Miscellaneous Biophytis to meet with FDA to advance Sarconeos (BIO101) development in Sarcopenia from Phase 2 to Phase 3 16-Dec-2021 / 08:00 CET/CEST Biophytis to meet with FDA to advance Sarconeos (BIO101) developm...
Nov 23, 2021	Biophytis obtains a new 10M? loan structure with Kreos Capital	Biophytis / Key word(s): Bond Biophytis obtains a new 10M? loan structure with Kreos Capital 22-Nov-2021 / 23:00 CET/CEST Biophytis obtains a new 10M? loan structure with Kreos Capital Paris (France), Cambridge (Massachusetts, U.S.), Novemb...
Nov 15, 2021	Biophytis announces US centers to restart recruitment for the COVA phase 2-3 study with Sarconeos (BIO101) in COVID-19	Biophytis / Key word(s): Miscellaneous Biophytis announces US centers to restart recruitment for the COVA phase 2-3 study with Sarconeos (BIO101) in COVID-19 15-Nov-2021 / 08:00 CET/CEST Biophytis announces US centers to restart recruitment...
Oct 29, 2021	Biophytis to Report Restated Financial Statements for Previous Periods and as of June 30, 2021	Biophytis / Mot-clé(s) : Autres Biophytis to Report Restated Financial Statements for Previous Periods and as of June 30, 2021 29-Oct-2021 / 08:00 CET/CEST ------------------------------------------------------------------------------------...
Oct 4, 2021	Biophytis Announces the Drawing of 2 New Tranches of ORNANE Under the 2020 Atlas Contract for €6 Million	PARIS and CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processe...
Jul 20, 2021	Biophytis S A : Judgment rendered on July 16, 2021 in the proceedings between Biophytis and Negma Group Ltd by the Execution Judge from the Paris Court of JusticeRead the presse release	Press Release Judgment rendered on July 16, 2021 in the proceedings between Biophytis and Negma Group Ltd by the Execution Judge from the Paris Court of Justice Paris, France, and Cambridge, Massachusetts, USA - July 19, 2021, 11:00 p.m. CE...
May 12, 2021	BIOPHYTIS S.A. Biophytis S A : All ordinary and extraordinary resolutions have been adopted (Form 6-K)	All ordinary and extraordinary resolutions have been adopted Paris, France, Cambridge (Massachusetts, United States), May 11, 2021, 8:00 am. CEST - - Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ('Biophytis' or the 'company...
Feb 15, 2021	Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market	ADS Offering of $20.1 million in gross proceeds closed on February 12, 2021. Biophytis’s ADSs began trading on the Nasdaq Capital Market on February 10, 2021. PARIS and CAMBRIDGE, Mass., Feb. 15, 2021 (GLOBE NEWSWIRE) -- Biophytis (NasdaqCM...
Feb 10, 2021	Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext Growth	PARIS and CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerat...
Jul 6, 2020	BIOPHYTIS Biophytis : announces the issuance of a 3 million tranche of ORNANE. Read the Press Release	Biophytis announces the issuance of a €3 million tranche of ORNANE Paris, (France), Cambridge (Massachusetts, United States), July 1, 2020; 9pm CEST - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company speci...
Dec 21, 2018	Colin Freund takes new CEO job at Modra Pharma; Compass recruits Pfizer, Biogen vets to C-suite	Colin Freund → Amsterdam-based Modra Pharmaceuticals has tapped a permanent CEO to guide its pipeline of oral chemotherapies as it wraps up a Phase Ib/IIa study for the lead program — a tablet formulation of docetaxel. ...
Oct 1, 2012	Biophytis Bags $2.6M Series B	PARIS, FRANCE, Research company in health and nutrition focusing on metabolic disorders and age-related diseases, announces today that it has raised EUR two million (USD 2.6M) in a B round. >> Click here for more funding data on Bi...
Oct 1, 2012	Biophytis Closes €2M Series B Financing	Biophytis, a Romainville (Seine-Saint-Denis), near Paris-based research company in health and nutrition focusing on metabolic disorders and age-related diseases, has raised €2m (approximately $2.6m) in Series B funding round. Metabrain Rese...

Reviews 0

FAQ about Biophytis - LIVE HEALTHIER LONGER

When was Biophytis - LIVE HEALTHIER LONGER founded?

Biophytis - LIVE HEALTHIER LONGER was founded in 2006.

How much funding has Biophytis - LIVE HEALTHIER LONGER raised?

Biophytis - LIVE HEALTHIER LONGER has raised $48.25M in total across 6 funding rounds.

What funding rounds has Biophytis - LIVE HEALTHIER LONGER raised?

Parsers VC lists 6 funding rounds of Biophytis - LIVE HEALTHIER LONGER, among them a funding round of $11.63M on Sep 13, 2018, a funding round of $8.74M on Nov 1, 2017 and a funding round of $12.34M on Oct 11, 2017.

What has the press written about Biophytis - LIVE HEALTHIER LONGER?

Parsers VC has collected 30 articles mentioning Biophytis - LIVE HEALTHIER LONGER, among them “Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing” (Mar 14, 2025) and “Biophytis Launches a Round of Fundraising for Approximately 2 Million Euros” (May 10, 2023).

Is Biophytis - LIVE HEALTHIER LONGER still active?

Yes, Biophytis - LIVE HEALTHIER LONGER is active; its latest activity on Parsers VC dates from Mar 13, 2026.